Published in Medical Letter on the CDC and FDA, June 13th, 2010
"This phase II trial enrolled in less than a year, driven by strong interest among clinical investigators and the ALCL patient community," said Thomas C. Reynolds, M.D., Ph.D., Chief Medical Officer of Seattle Genetics....
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA